BioNTech shrinks CAR-T front line, laying off 63 people.

German biotechnology company BioNTech plans to reduce the production scale of its cell therapy at the company's first factory in the United States, as its CAR-T candidate drug did not meet expectations in early cancer trials. At the end of this summer, BioNTech's cell therapy factory in Gaithersburg, Maryland will lay off 63 employees, mainly affecting the cell therapy technology operations team at the site.